Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer.
Parikh AR, Lee FC, Yau L, Koh H, Knost J, Mitchell EP, Bosanac I, Choong N, Scappaticci F, Mancao C, Lenz HJ. Parikh AR, et al. Clin Cancer Res. 2019 May 15;25(10):2988-2995. doi: 10.1158/1078-0432.CCR-18-1221. Epub 2018 Sep 17. Clin Cancer Res. 2019. PMID: 30224341 Free PMC article. Clinical Trial.
Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer.
Barat A, Smeets D, Moran B, Zhang W, Cao S, Das S, Klinger R, Betge J, Murphy V, Bacon O, Kay EW, Van Grieken NCT, Verheul HMW, Gaiser T, Schulte N, Ebert MP, Fender B, Hennessy BT, McNamara DA, O'Connor D, Gallagher WM, Cremolini C, Loupakis F, Parikh A, Mancao C, Ylstra B, Lambrechts D, Lenz HJ, Byrne AT, Prehn JHM. Barat A, et al. Sci Rep. 2020 Jun 17;10(1):9778. doi: 10.1038/s41598-020-65869-2. Sci Rep. 2020. PMID: 32555399 Free PMC article.
Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Arai H, Xiao Y, Millstein J, Wang J, Battaglin F, Kawanishi N, Jayachandran P, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Parikh AR, Lenz HJ. Arai H, et al. Among authors: parikh ar. Br J Cancer. 2022 Jan;126(1):72-78. doi: 10.1038/s41416-021-01592-7. Epub 2021 Oct 23. Br J Cancer. 2022. PMID: 34689170 Free PMC article. Clinical Trial.
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial.
Lenz HJ, Parikh A, Spigel DR, Cohn AL, Yoshino T, Kochenderfer M, Elez E, Shao SH, Deming D, Holdridge R, Larson T, Chen E, Mahipal A, Ucar A, Cullen D, Baskin-Bey E, Kang T, Hammell AB, Yao J, Tabernero J. Lenz HJ, et al. J Immunother Cancer. 2024 Mar 13;12(3):e008409. doi: 10.1136/jitc-2023-008409. J Immunother Cancer. 2024. PMID: 38485190 Free PMC article. Clinical Trial.
Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.
Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS. Kamran SC, et al. Among authors: parikh ar. Cancer Med. 2018 Jul;7(7):2934-2942. doi: 10.1002/cam4.1558. Epub 2018 May 17. Cancer Med. 2018. PMID: 29771009 Free PMC article.
Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis.
Fong ZV, Verdugo FL, Fernandez-Del Castillo C, Ferrone CR, Allen JN, Blaszkowsky LS, Clark JW, Parikh AR, Ryan DP, Weekes CD, Hong TS, Wo JY, Lillemoe KD, Qadan M. Fong ZV, et al. Among authors: parikh ar. J Am Coll Surg. 2023 Jun 1;236(6):1126-1136. doi: 10.1097/XCS.0000000000000499. Epub 2022 Dec 8. J Am Coll Surg. 2023. PMID: 36729817
136 results